Cipla Usa Drug Patent Portfolio
Cipla Usa owns 1 orange book drug protected by 4 US patents Given below is the list of Cipla Usa's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8383596 | Antibacterial aminoglycoside analogs | 02 Jun, 2031 | Active |
| US8822424 | Antibacterial aminoglycoside analogs | 21 Nov, 2028 | Active |
| US9266919 | Antibacterial aminoglycoside analogs | 21 Nov, 2028 | Active |
| US9688711 | Antibacterial aminoglycoside analogs | 21 Nov, 2028 | Active |
Latest Legal Activities on Cipla Usa's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Cipla Usa.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
FDA Final Eligibility Letter
Critical
| 30 Jan, 2024 | US8822424 |
|
FDA Final Eligibility Letter
Critical
| 30 Jan, 2024 | US8383596 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 23 Aug, 2023 | US9266919 |
| transaction for FDA Determination of Regulatory Review Period | 15 May, 2023 | US8383596 |
| transaction for FDA Determination of Regulatory Review Period | 15 May, 2023 | US8822424 |
| transaction for FDA Determination of Regulatory Review Period | 18 Apr, 2023 | US8383596 |
| transaction for FDA Determination of Regulatory Review Period | 18 Apr, 2023 | US8822424 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 02 Mar, 2022 | US8822424 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 28 Dec, 2020 | US9688711 |
| Second letter to regulating agency to determine regulatory review period | 24 Sep, 2020 | US8822424 |
| Second letter to regulating agency to determine regulatory review period | 24 Sep, 2020 | US8383596 |
| 7.5 yr surcharge - late pmt w/in 6 mo, Small Entity | 28 Aug, 2020 | US8383596 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 28 Aug, 2020 | US8383596 |
|
Email Notification
Critical
| 14 May, 2020 | US8822424 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 14 May, 2020 | US8383596 |
Cipla Usa's Family Patents
Cipla Usa Drug List
Given below is the complete list of Cipla Usa's drugs and the patents protecting them.
1. Zemdri
Zemdri is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8383596 | Antibacterial aminoglycoside analogs |
02 Jun, 2031
(5 years from now)
| Active |
| US8822424 | Antibacterial aminoglycoside analogs |
21 Nov, 2028
(3 years from now)
| Active |
| US9266919 | Antibacterial aminoglycoside analogs |
21 Nov, 2028
(3 years from now)
| Active |
| US9688711 | Antibacterial aminoglycoside analogs |
21 Nov, 2028
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zemdri's drug page